$SYK

STRYKER CORP

Stryker develops and sells medical technologies and related services to doctors, hospitals and other healthcare facilities. Its products are sold in approximately 61 countries through company-owned subsidiaries and branches, as well as third-party dealers and distributors. Stryker has two reportable segments: MedSurg and Neurotechnology, which includes surgical equipment, endoscopy and communications systems, patient handling and emergency care products, virtual care technology, and products for stroke and brain surgery; and Orthopaedics, which includes implants for joint replacement, trauma and extremities procedures, and Mako robotic-arm assisted technology. Stryker makes money by selling its products, most of which are marketed directly to healthcare professionals and facilities. The company is headquartered in Portage, Michigan.

1
0
0
—
$178.9M
STRYKER RONDA E
0%
See all $SYK insider activity →

Stryker Board Expands with Healthcare Executive James Davis

Stryker (SYK) expanded its board to 12 members, electing James E. Davis, CEO of Quest Diagnostics, as the new director. Davis brings healthcare and medical technology experience. SYK stock has a Buy rating with a $350 price target, according to analysts, and is rated Outperform by TipRanks' AI Analyst, citing strong financial performance but noting rich valuation and near-term overbought technicals.

SYK sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning SYK (STRYKER CORP). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.

Recent SYK coverage spans financial news, corporate actions and insider activity.

In the last 30 days, SYK insiders filed 6 SEC Form 4 transactions — no purchases and 6 sales ($178.9M). The most active reporter was STRYKER RONDA E with 6 filings.

What's driving SYK

AlphAI scores every news story that mentions SYK with an AI model for sentiment and relevance, and aggregates insider trades from STRYKER CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $SYK

Score

Stryker Board Expands with Healthcare Executive James Davis

Stryker (SYK) expanded its board to 12 members, electing James E. Davis, CEO of Quest Diagnostics, as the new director. Davis brings healthcare and medical technology experience. SYK stock has a Buy rating with a $350 price target, according to analysts, and is rated Outperform by TipRanks' AI Analyst, citing strong financial performance but noting rich valuation and near-term overbought technicals.

$SYKLowExec change· appointed

STRYKER CORP (SYK): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

STRYKER CORP (SYK) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 1941 Stryker Way Portage, MI 49002 www.stryker.com November 9, 2026 Press release Stryker announces intention to nominate Jim Davis to board of directors PORTAGE, Mich. – Nov. 9, 2026 – Stryker (NYSE:SYK) announced that its board of directors has nominated Jim Davis

Stryker (SYK) Stock May Be 22% Undervalued On Manufacturing Issues

Stryker (SYK) has faced manufacturing issues and shifting demand, raising questions about its valuation. The company's 5-year share price return is 34.1%, with a P/E ratio of 35.2x. Analysts project growing free cash flows, estimating intrinsic value higher than the current share price of $335.08. Insider trading and market sentiment are mixed, with some seeing upside potential and others viewing it as overvalued.

Bulgaria accepts first five US M1126 Stryker ICV armored vehicles under $1.4 billion Army modernization.

Bulgaria has received the first five of 183 Stryker armored vehicles under a $1.4 billion modernization deal. The order includes various configurations, with deliveries delayed due to component shortages. General Dynamics Land Systems-Canada manufactures the vehicles, and TEREM-Ivaylo handles final assembly and testing. The project's cost has increased by 2.76% due to inflation and other factors.

Stryker, Omnicell, Zimmer Biomet, Artivion, and Dentsply Sirona shares are soaring, what you need to know

Shares of Stryker, Omnicell, Zimmer Biomet, Artivion, and Dentsply Sirona surged after Democrats reclaimed majorities in the House and Senate, easing regulatory uncertainty around drug pricing. Analysts expect the biopharmaceutical sector to strengthen. Stryker (SYK) rose 8.8%, Omnicell (OMCL) 10.8%, Zimmer Biomet (ZBH) 15.2%, Artivion (AORT) 9.1%, and Dentsply Sirona (XRAY) 9.2%. Zimmer Biomet's shares hit a 52-week high of $111.96.

$ZBHHighAI 9/10

Zimmer Biomet Soars 15% as Hip and Tech Growth Lifts Guidance, “Validating the Progress” of Its Strategy

Zimmer Biomet (ZBH) shares rose 15% after Q3 sales grew 3.7% in constant currency, with hips, sports medicine, and technology segments growing 7% or more. The company raised its 2026 guidance, citing progress in diversification. Knees, 37% of sales, declined 2.6%. Rival Stryker (SYK) and Smith & Nephew (SNN) also saw gains, despite Smith & Nephew cutting its outlook.

Related tickers